[Tumor Immunogenicity and Immune Checkpoint Inhibitors].
Gan To Kagaku Ryoho
; 49(9): 922-927, 2022 Sep.
Article
en Ja
| MEDLINE
| ID: mdl-36156006
ABSTRACT
Cancer immunotherapy including immune checkpoint inhibitors(ICIs)have established itself as the fourth cancer therapy. However, the response rate of ICIs is still only about 20%, and tumors resistant to ICIs are often so-called"cold-tumor"with low tumor immunogenicity. Therefore, research and development is being conducted worldwide on how to convert cold- tumors into hot-tumors with high immunogenicity. In this paper, we review the relationship between tumor immunogenicity and ICI, as well as therapeutic methods to enhance tumor immunogenicity, and introduce our research about novel cancer peptide vaccination therapy.
Buscar en Google
Base de datos:
MEDLINE
Asunto principal:
Vacunas contra el Cáncer
/
Neoplasias
Idioma:
Ja
Revista:
Gan To Kagaku Ryoho
Año:
2022
Tipo del documento:
Article